However, a flow cytometry analysis of EVs collected from metastatic melanoma patients treated with an immunotherapeutic agent, the monoclonal antibody ipilimumab, showed, at baseline, that the levels of EV-PD1 and CD28 from T-cells were associated with improved PFS and overall survival [171]. This evidence concerns the gene CD28 and metastatic melanoma.